137 related articles for article (PubMed ID: 15768351)
1. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.
Reimer J; Schulte B; Castells X; Schafer I; Polywka S; Hedrich D; Wiessing L; Haasen C; Backmund M; Krausz M
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S373-8. PubMed ID: 15768351
[TBL] [Abstract][Full Text] [Related]
2. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
3. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection.
Dore GJ; Thomas DL
Semin Liver Dis; 2005 Feb; 25(1):18-32. PubMed ID: 15731995
[TBL] [Abstract][Full Text] [Related]
4. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
5. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
6. Treating hepatitis C virus infection in active substance users.
Sylvestre DL
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S321-4. PubMed ID: 15768341
[TBL] [Abstract][Full Text] [Related]
7. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
Kresina TF; Bruce RD; Cargill VA; Cheever LW
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C in drug addicts: access and treatment compliance].
Sarmento E Castro R; Valente C; Ramos JP; Almeida JR; Marinho RT; Branco T; Andrade S; Macedo A
Acta Med Port; 2011 Dec; 24 Suppl 2():483-92. PubMed ID: 22849938
[TBL] [Abstract][Full Text] [Related]
9. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
Litwin AH; Soloway I; Gourevitch MN
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
[TBL] [Abstract][Full Text] [Related]
10. Medical management of HIV-hepatitis C virus coinfection in injection drug users.
Khalsa JH; Kresina T; Sherman K; Vocci F
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S1-6. PubMed ID: 16265605
[TBL] [Abstract][Full Text] [Related]
11. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
12. Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance.
Donoghoe MC; Verster A; Pervilhac C; Williams P
Int J Drug Policy; 2008 Apr; 19 Suppl 1():S5-14. PubMed ID: 18243681
[TBL] [Abstract][Full Text] [Related]
13. Integrating HCV services for drug users: a model to improve engagement and outcomes.
Sylvestre DL; Zweben JE
Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
[TBL] [Abstract][Full Text] [Related]
14. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan.
Liu JY; Lin HH; Liu YC; Lee SS; Chen YL; Hung CC; Ko WC; Huang CK; Lai CH; Chen YS; Shih YL; Chung HC; Liang SH; Lin JN
Clin Infect Dis; 2008 Jun; 46(11):1761-8. PubMed ID: 18433337
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C in injection drug users: It is time to treat.
Grassi A; Ballardini G
World J Gastroenterol; 2017 May; 23(20):3569-3571. PubMed ID: 28611509
[TBL] [Abstract][Full Text] [Related]
16. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
17. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
18. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.
de la Fuente L; Toro C; Soriano V; Brugal MT; Vallejo F; Barrio G; Jiménez V; Silva T;
J Clin Virol; 2006 Mar; 35(3):244-9. PubMed ID: 16143565
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
20. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union.
Wolfe D
Int J Drug Policy; 2007 Aug; 18(4):246-54. PubMed ID: 17689372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
